BioNTech (NASDAQ:BNTX) Posts Earnings Results, Beats Estimates By $0.26 EPS

BioNTech (NASDAQ:BNTX) issued its quarterly earnings results on Tuesday. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.26, FiscalAI reports. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. The company had revenue of $136.59 million during the quarter, compared to the consensus estimate of $207.43 million. During the same quarter in the previous year, the firm earned ($1.73) earnings per share. The firm’s quarterly revenue was down 35.4% on a year-over-year basis.

Here are the key takeaways from BioNTech’s conference call:

• BioNTech is pivoting to a tumor‑centric, combination‑first oncology strategy with a focus on high‑incidence cancers and aims for more than 17 late‑stage/pivotal readouts through 2030 and five additional late‑stage readouts in 2026, signaling large future catalyst potential.
• Early clinical data support the approach — pumitamab Phase I‑B/II‑A showed a 46% confirmed ORR (median PFS 13.6 months, median OS 27 months) and a 71% ORR in PD‑L1 high squamous NSCLC, underpinning the ongoing global Phase III ROSETTA LUNG‑02 program.
• Gotistobart’s non‑pivotal data are encouraging — PRESERVE‑003 interim showed a 54% reduction in risk of death versus docetaxel (HR 0.46) and a 12‑month PFS of 25% vs 0, but management notes the sample is small and requires validation in the pivotal stage later this year.
• Strong balance sheet and shareholder returns — BioNTech ended Q1 with EUR 16.8 billion in cash/securities, reaffirmed 2026 guidance (EUR 2.0–2.3bn revenues) and announced an opportunistic $1 billion ADS share buyback, supporting capital allocation alongside R&D investment.
• Management plans to consolidate manufacturing (potentially exiting sites in Idar‑Oberstein, Marburg and Singapore), affecting ~1,800 positions while targeting about EUR 500 million in recurring annual savings; near‑term execution risks and one‑time charges are possible even as long‑term efficiency improves.

BioNTech Stock Down 2.2%

Shares of NASDAQ BNTX traded down $2.18 during mid-day trading on Tuesday, reaching $97.17. The company had a trading volume of 229,062 shares, compared to its average volume of 1,079,016. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $97.52 and a two-hundred day simple moving average of $101.12. The stock has a market cap of $24.57 billion, a P/E ratio of -18.51 and a beta of 1.36. BioNTech has a 52-week low of $79.52 and a 52-week high of $124.00.

Insider Activity at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the transaction, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at $44,156,226.72. This trade represents a 11.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. boosted its stake in BioNTech by 9.0% during the 4th quarter. Invesco Ltd. now owns 80,841 shares of the company’s stock worth $7,696,000 after purchasing an additional 6,685 shares during the period. Alberta Investment Management Corp acquired a new stake in BioNTech during the 4th quarter worth $1,021,000. Krensavage Asset Management LLC boosted its stake in BioNTech by 25.4% during the 4th quarter. Krensavage Asset Management LLC now owns 99,523 shares of the company’s stock worth $9,475,000 after purchasing an additional 20,157 shares during the period. Mackenzie Financial Corp boosted its stake in BioNTech by 4.5% during the 4th quarter. Mackenzie Financial Corp now owns 4,485 shares of the company’s stock worth $428,000 after purchasing an additional 195 shares during the period. Finally, XTX Topco Ltd boosted its stake in BioNTech by 90.4% during the 4th quarter. XTX Topco Ltd now owns 28,180 shares of the company’s stock worth $2,683,000 after purchasing an additional 13,382 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on BNTX shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and set a $130.00 price target on shares of BioNTech in a report on Monday, April 27th. Leerink Partners cut shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target for the company. in a report on Monday, February 2nd. Citigroup lowered their price target on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Finally, TD Cowen lowered their price target on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.13.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.